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Abstract
OBJECTIVE: To study changes in the nuclear fac-
tor-κB p65 (NF-κB p65)-inducible nitric oxide syn-
thase (iNOS)-nitric oxide (NO) signaling pathway
and the effects of Xinfeng capsules (XFC) in pa-
tients with ankylosing spondylitis (AS)
METHODS: One hundred twenty patients with AS
were randomly divided into an XFC group and a
Salazopyrin group. Sixty health subjects were in-
cluded as a normal control group. In the two treat-
ment groups, pulmonary functional parameters,
forced vital capacity (FVC), forced expiratory vol-
ume in 1 second (FEV1), maximal voluntary ventila-
tion (MVV), peak expiratory flow (PEF), forced expi-
ratory flow at 25% of forced vital capacity (FEF25),
forced expiratory flow at 50% of forced vital capaci-
ty (FEF50), and forced expiratory flow at 75% of
forced vital capacity (FEF75) were determined. En-
zyme linked immunosorbent assays were used for
detection of the serum oxidative stress indexes,
NF-κB p65, iNOS, NO, reactive oxygen species
(ROS), reactive nitrogen species (RNS), malondialde-
hyde (MDA), superoxide dismutase (SOD), catalase
(CAT), total antioxidative capacity (TAOC) and inter-
leukin-4 (IL-4), IL-10, IL-1β, and tumor necrosis fac-
tor-α (TNF-α) contents. Westergren's method was
used for determination of erythrocyte sedimenta-
tion rate (ESR). High-sensitivity C-reactive protein
(Hs-CRP) was detected with a 7060 full-automatic
biochemical analyzer (Hitachi, Japan).
RESULTS: The clinical therapeutic effect in the XFC
group was significantly superior to that in the Sala-
zopyrin group (P<0.01). Compared with the normal
control group, FEV1, MVV, PEF, FEF50, FEF75, SOD, CAT,
TAOC, IL-4, IL-10 were significantly lower, and NF-κB
p65, iNOS, NO, ROS, RNS, MDA, IL-1β, TNF-α, ESR,
and Hs-CRP significantly higher in patients with AS
(P<0.01 or P<0.05). Compared with before treat-
ment, FEV1, MVV, PEF, FEF50, FEF75, SOD, CAT, TAOC,
IL-4, and IL-10 were significantly increased, and
NF-κB p65, iNOS, NO, ROS, RNS, MDA, IL-1β, TNF-α,
ESR, CRP, visual analog scales (VAS), Bath ankylos-
ing spondylitis disease active index, Bath ankylos-
ing spondylitis functional index, and Bath ankylos-
ing spondylitis global index significantly decreased
in the two treatment groups after treatment (P<
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0.01 or P<0.05), with significant differences be-
tween the XFC and Salazopyrin groups (P<0.01 or
P<0.05). Spearman correlation analysis indicated
that FEV1, MVV, PEF, FEF50, and FEF75 were positively
correlated with SOD, CAT, TAOC, IL-4, and IL-10, and
were negatively correlated with NF-κB p65, iNOS,
NO, ROS, RNS, MDA, IL-1β, TNF-α, ESR, and CRP.
CONCLUSION: Patients with AS have local patho-
logic changes in the spinal cord and other joints.
They also have decreased pulmonary function,
which is negatively correlated with the NF-κB-iN-
OS-NO signaling pathway, oxidative indexes, and in-
flammatory factors. XFC improves rigidity and pain
in spinal joints and other symptoms, laboratory in-
dexes, and pulmonary function. The mechanism is
possibly related to inhibition of the NF-κB-iNOS-NO
signaling pathway.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Ankylosing spondylitis (AS) is a chronic, progressive,
autoimmune disease that causes chronic inflammation
of the sacroiliac joint and spinal cord middle axis
joints. The lung is often affected in patients with AS
because the lung is rich in connective tissues and blood
vessels. A prospective study indicated that the inci-
dence rate of AS-induced pulmonary affection is
1.5%-30%.1 AS invasion is likely related to infection,
heredity, and immunity, but the exact pathological
mechanism is not known.
Studies2-7 indicate that increases in oxidative level and
decreases in anti-oxidative capability are possibly relat-
ed to AS onset. However, there are no reports about
whether or not changes in pulmonary functions in le-
sions outside joints induced by AS are related to oxida-
tive stress disturbance. It is also unclear what role that
the nuclear factor-κB p65 (NF-κB p65)-inducible ni-
tric oxide synthase (iNOS)-nitric oxide (NO) signal
pathway plays in pulmonary function injury. In this
study, changes in pulmonary functions and expressions
of serum NF-κB, iNOS, and other indexes before and
after treatment with Xinfeng capsule in patients with
AS were observed and comparatively analyzed to study
the mechanism of Xinfeng capsule improving pulmo-
nary functions of the patient.
MATERIALS ANDMETHODS
Subjects
One hundred twenty patients with AS were selected
from inpatients in the Department of Rheumatism,
the First Affiliated Hospital of Anhui University of
Traditional Chinese Medicine between September
2012 and October 2013. Among them, 100 were male
and 20 were female (5∶1). Patients were between
18-60 years old, averaging (28 ± 10) years. Disease
course was 0.5-31 years, with an average of (10 ± 8)
years. Patients were randomly divided by random table
into an XFC group and a Salazopyrin group, with 60
patients in each group. There were no statistically sig-
nificant differences between the two groups in the ba-
sic data (P>0.05). A normal control group (NC group,
n=60) was selected from the Center of Physical Exami-
nation, the First Affiliated Hospital of Anhui Universi-
ty of Traditional Chinese Medicine. The NC group
had 50 males and 10 females, aged between 23-51
years, averaging (29±10) years. NC patients had no au-
toimmune diseases or evident organic diseases, and
were taking no immune modulators. This experiment
was approved by Ethics Committee of the First Affiliat-
ed Hospital of Anhui University of Traditional Chi-
nese Medicine, and the patients gave informed consent.
Diagnostic criteria
Diagnostic criteria were in accordance with the New
York Diagnostic Criteria of AS8 revised by American
Society of Rheumatism in 1984 and the Classifica-
tion Criteria of Spondyloarthritis (SpA) of Axial
Type9 issued by Assessment of SpondyloArthritis In-
ternational Society Working Group (ASAS) in
March 2009.
Inclusion criteria
Patients were included if they conformed to AS diag-
nostic criteria and gave informed consent. All patients
were able to strictly follow medical orders.
Exclusion criteria
Patients were not included if they had ankylosing
changes in the spinal cord with severe deformations.
Pregnant or breast-feeding patients were excluded. Pa-
tients were excluded if they had other serum negative
spinal joint diseases, or other severe diseases that re-
quire treatment with adrenocortical hormones. Pa-
tients with severe heart, brain, kidney, and other organ
diseases were excluded.
Treatment program
The NC group individuals who had no obvious organ-
ic disease as assessed by somatoscopy and immunologic
testing didn't take any medicines. Patients in the XFC
group were given XFC (produced by the Pharmaceu-
tics Room, the First Affiliated Hospital of Anhui Uni-
versity of Traditional Chinese Medicine, Wan Yao Zhi
Zi No. Z20050062, Batch No. 201205291, Stan-
dards: 0.5 g/capsule, Anhui, China) 3 capsules each
time, three times a day with 3 months constituting one
course. Patients in the Salazopyrin group were given
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Salazopyrin (produced by Shanghai Sanwei Pharmacy
Co., Ltd., Guoyao Zun Zi No. H31020450, Batch
No. 201104c20, Standards: 0.25 g/tablet, Shanghai,
China), 4 tablets each time, twice per day, with the
same days of administration and therapeutic course as
the XFC group. During the treatment the medicines
for symptomatic treatment were not changed in the
two groups. If necessary, non-steroidal anti-inflamma-
tory drugs of equal dosages could be added in the two
groups.
Indexes of assessment of therapeutic effects
Visual analog scales (VAS), Bath ankylosing spondyli-
tis disease active index (BASDAI), Bath ankylosing
spondylitis functional index (BASFI), and Bath anky-
losing spondylitis global index (BAS-G) were used for
scoring (0-10) patients with AS. A higher score indicat-
ed a more severe illness stage.
Determination of pulmonary function
German Jager MasterScreen automatic pulmonary
function detector was used and EasyOneTM diagnostic
spirometer was from NDD Medizintechnik AG
(CH-8005, Zurich, Switzerland). After the patients
were forbidden to smoke for 2 weeks, forced vital ca-
pacity (FVC), forced expiratory volume in 1 second
(FEV1), maximal voluntary ventilation (MVV), peak
expiratory flow (PEF), forced expiratory flow at 25%
of forced vital capacity (FEF25), forced expiratory flow
at 50% of forced vital capacity (FEF50), and forced expi-
ratory flow at 75% of forced vital capacity (FEF75) were
determined. To eliminate effects of sex, age, body
height, body weight and other factors, the parameters
are expressed as the determined value/normal predicted
value (%). For indexes of pulmonary functions, a deter-
mined value/normal predicted value <80% was regard-
ed as abnormal.
Determination of serum erythrocyte sedimentation
rate (ESR), high-sensitivity C-reactive protein
(Hs-CRP)
Five milliliters of venous blood was taken from fasted
patients in the morning, and immediately sent to the
Experimental Center of the First Affiliated Hospital,
Anhui University of Traditional Chinese Medicine for
detection. ESR (mm/h) was detected with Wester-
gren's method and Hs-CRP (mg/L) was determined
with Hitachi 7060 full-automatic biochemical analyzer.
Detection of serum NF-κB p65, iNOS, NO, ROS,
RNS, MDA, SOD, CAT, TAOC, IL-1β, TNF-α, IL-4,
and IL-10 levels
NF-κB p65, iNOS, NO, reactive oxygen species
(ROS), reactive nitrogen species (RNS), malondialde-
hyde, (MDA), superoxide dismutase (SOD), catalase
(CAT), total antioxidative capacity (TAOC), interleu-
kin-1β (IL-1β), tumor necrosis factor-α (TNF-α),
IL-4, and IL-10 levels were detected with enzyme
linked immunosorbent assays (ELISA).
Ten milliliters venous blood were taken from the pa-
tient with fasting in the morning, and centrifuged for
15 min at 3000 ×g. Then, the supernatant was equal-
ly divided into four aliquots and kept at ﹣ 80℃ .
NF-κB p65, iNOS, and NO ELISA kits were pur-
chased from Shanghai Yuanye Bio-Technology Co.,
Ltd. (Shanghai, China). ROS, RNS, MDA, SOD,
CAT, and TAOC ELISA kits were purchased from
Nanjing Jiancheng Bioengineering Institution. IL-1β,
TNF-α, IL-4, and IL-10 ELISA kits were purchased
from R&D Systems (Emeryville, CA, USA). Determi-
nations were conducted strictly following the direc-
tions of the kits.
Statistical analysis
SPSS 17.0 software (IBM Co., Armonk, NY, USA)
was used for statistical analysis of the data. The contin-
uous variable experimental data are expressed as mean±
standard deviation ( xˉ ±s). Kolmogorov-Smirnov test of
normality was used for the samples. T-test was used for
measurement data and χ2 test for enumeration data.
Spearman software was used for correlation analysis. P<
0.05 or P<0.01 was regarded as a statistically signifi-
cant difference.
RESULTS
This study was conducted as follows (Figure 1). One
hundred and twenty AS patients were recruited and di-
vided into 2 groups.
Comparison of clinical therapeutic effects
ASAS20 (a 20% response in the Assessment of Spondy-
loArthritis International Society Working Group Crite-
ria) and BASDAI50 (an improvement of 50% or more
in the BASDAI) were used for assessment of clinical
therapeutic effects. The results indicated that ASAS20
and BASDAI50 in the XFC group were 93.3% (56/
60) and 91.7% (55/60), respectively. In the Salazo-
pyrin group the respective scores were 71.7% (43/60)
and 66.7% (40/60). There was a significant difference
between the two groups (P<0.01), suggesting that the
clinical therapeutic effect in the XFC group is better
than that in the Salazopyrin group.
Comparisons of pulmonary function parameters,
peripheral blood oxidative stress indexes, cytokines,
and inflammatory indexes between the AS and NC
groups
Compared with the NC group, FEV1, MVV, PEF,
FEF50, FEF75, SOD, CAT, TAOC, IL-4, and IL-10 lev-
els were significantly lower, and NF-κB p65, iNOS,
NO, ROS, RNS, MDA, IL-1β, TNF-α, ESR, and
Hs-CRP levels were significantly higher in the AS
group (P<0.01 or P<0.05, Table 1).
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Comparisons of pulmonary function parameters,
peripheral blood oxidative stress indexes, cytokines,
inflammatory indexes, and therapeutic effect index
cumulative scores before and after treatment in the
two treatment groups
Before treatment, there were no significant differences
between the XFC group and the Salazopyrin group in
pulmonary function parameters, oxidative stress index-
es, cytokines, inflammatory indexes, and therapeutic ef-
fects (P>0.05). Compared with before treatment,
FEV1, MVV, PEF, FEF25, FEF50, FEF75, SOD, CAT,
TAOC, IL-4, and IL-10 significantly increased after
treatment, and NF-κB p65, iNOS, NO, ROS, RNS,
MDA, IL-1β, TNF-α, ESR, Hs-CRP, VAS, BASDAI,
BASFI, and BAS-G significantly decreased (P<0.01 or
P<0.05) in the two groups. There was a significant dif-
ference between the two treatment groups in the above
indexes (P<0.01 or P<0.05, Table 2).
Correlativity of pulmonary functional parameters to
oxidative stress, cytokines, inflammatory indexes,
and therapeutic effect index cumulative scores in
patients with AS
Spearman correlation analysis indicated that in pa-
tients with AS, FEV1, MVV, PEF, FEF25, FEF50, and
FEF75 were negatively correlated with NF-κB p65, iN-
OS, NO, ROS, RNS, MDA, IL-1β, TNF-α, ESR,
Figure1 Diagram of the test procedure
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; MVV: maximal voluntary ventilation; PEF: peak expiratory
flow; FEF25: forced expiratory flow at 25% of forced vital capacity; FEF50: forced expiratory flow at 50% of forced vital capacity;
FEF75: forced expiratory flow at 75% of forced vital capacity; NF-κB p65: nuclear factor-κB p65; iNOS: inducible nitric oxide syn-
thase; NO: nitric oxide; ROS: reactive oxygen species; RNS: reactive nitrogen species; MDA: malondialdehyde; SOD: Superoxide
dismutase; CAT: catalase; TAOC: total anti-oxidative capacity; IL-1β: interleukin-1β; TNF-α: tumor necrosis factor-α; IL-4: interleu-
kin-4; IL-10: interleukin-10; ESR: erythrocyte sedimentation rate; Hs-CRP: high-sensitivity C-reactive protein; VAS: visual analog
scales; BASDAI: bath ankylosing spondylitis disease active index; BASFI: bath ankylosing spondylitis functional index; BAS-G: Bath
ankylosing spondylitis global index; XFC: Xinfeng capsules.
The AS patients were randomly
divided into 2 groups (n=120)
Normal control group
(n=60)
XFC group
(n=60)
Salazopyrin group
(n=60)
FVC, FEV1, MVV,
PEF, FEF25, FEF50,
FEF75, NF-κB p65,
iNOS, NO, ROS,
RNS, MDA, SOD,
CAT, TAOC, IL-1β,
TNF-α, IL-4, IL-10,
ESR, Hs-CRP are
determined
(n=60)
FVC, FEV1, MVV, PEF,
FEF25, FEF50, FEF75,
NF-κB p65, iNOS, NO,
ROS, RNS, MDA,
SOD, CAT, TAOC,
IL-1β, TNF-α, IL-4,
IL-10, ESR, Hs-CRP are
determined and VAS,
BASDAI, BASFI, BAS-G
are assessed before
treatment (n=60)
FVC, FEV1, MVV, PEF,
FEF25, FEF50, FEF75,
NF-κB p65, iNOS, NO,
ROS, RNS, MDA,
SOD, CAT, TAOC,
IL-1β, TNF-α, IL-4,
IL-10, ESR, Hs-CRP are
determined and VAS,
BASDAI, BASFI, BAS-G
are assessed before
treatment (n=60)
Treated without
any drugs (n=60)
Treated with
XFC (n=60)
Treated with
Salazopyrin (n=60)
3 months after treatment,
FVC, FEV1, MVV, PEF,
FEF25, FEF50, FEF75,
NF-κB p65, iNOS, NO,
ROS, RNS, MDA, SOD,
CAT, TAOC, IL-1β,
TNF-α, IL-4, IL-10, ESR,
Hs- CRP are determined.
VAS, BASDAI, BASFI,
BAS-G are assessed (n=60)
3 months after treatment,
FVC, FEV1, MVV, PEF,
FEF25, FEF50, FEF75,
NF-κB p65, iNOS, NO,
ROS, RNS, MDA, SOD,
CAT, TAOC, IL-1β,
TNF-α, IL-4, IL-10, ESR,
Hs- CRP are determined.
VAS, BASDAI, BASFI,
BAS-G are assessed (n=60)
Conclusion on data processing and
statistic analysis (n=120)
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Hs-CRP, and symptom and sign cumulative score, and
were positively correlated with SOD, CAT, TAOC,
IL-4, and IL-10 (P<0.01 or P<0.05, Table 3).
Correlativity of expressions of peripheral bloodNF-κBp65, iNOS, andNOwith oxidative stress indexes,
cytokines, andother indexes inpatientswithAS
Spearman correlation analysis showed in patients with
AS, NF-κB p65 expression was positively correlated
with ROS, RNS, MDA, TNF-α, and ESR, and nega-
tively with SOD, TAOC, IL-4, and IL-10. iNOS ex-
pression was positively correlated with ROS, RNS,
MDA, TNF-α, and Hs-CRP, and negatively correlat-
ed with SOD, TAOC. NO expression was positively
correlated with ROS, MDA, IL-1β, ESR, Hs-CRP,
and negatively correlated with SOD, TAOC (P<0.01
or P<0.05, Table 4).
DISCUSSION
NF-κB-iNOS-NO signaling is an important oxidative
stress pathway.10 NF-κB is a nucleoprotein first detect-
ed in an extract from B lymphocyte nuclei.11 In normal
cells, NF-κB is primarily in the form of P50-P65 di-
mer, and combined with an inhibitory protein -α
(IκB-α) in the cytoplasm in the inactive state. When
stimulated by ROS, RNS, or other free radicals, IκB-α
becomes phosphorylated, which dissociates it from
P50-P65, leading to activation of NF-κB, and induc-
ing tissue lesions.12 AS is an autoimmune disease that
causes chronic inflammation of the sacroiliac joint and
spinal cord middle axis joints. If AS is not diagnosed
and treated at an early stage, then diseases of the con-
nective tissue outside of the joints can occur.13,14 The
lung is rich in connective tissues and blood vessels, so
Table 1 Comparisons of pulmonary function parameters, peripheral blood oxidative stress and other indexes between the AS and
NC groups ( xˉ ±s)
Index
FVC (mL)
FEV1 (mL)
MVV (mL)
PEF (mL/s)
FEF25 (mL/s)
FEF50 (mL/s)
FEF75 (mL/s)
NF-κB p65 (ng/mL)
iNOS (U/mL)
NO (μmol/L)
ROS (ng/mL)
RNS (U/mL)
MDA (nmol/mL)
SOD (U/mL)
CAT (ku/L)
TAOC (U/mL)
IL-1β (pg/mL)
TNF-α (ng/L)
IL-4 (ng/L)
IL-10 (ng/L)
ESR (mm/h)
Hs-CRP (mg/L)
NC group (n=60)
92.41±23.53
104.92±12.53
101.21±27.98
87.53±17.62
83.26±25.11
94.58±32.17
91.73±17.36
2.31±1.45
16.47±10.26
196.43±97.35
2.80±0.11
98.93±5.74
11.86±5.39
165.86±44.49
298.37±132.25
3.06±0.61
2.43±1.68
18.78±11.47
408.32±231.23
169.45±34.16
9.16±3.57
1.85±0.76
AS group (n=120)
89.65±25.87
82.53±17.16a
87.12±19.27a
65.34±12.21a
83.41±24.83
83.25±24.15a
76.36±20.58a
3.73±2.03a
22.83±12.38a
275.24±180.23a
3.85±0.47a
131.23±22.28a
32.61±17.63a
132.58±37.36b
223.32±119.85a
2.04±0.21a
3.83±2.26a
278.69±158.47a
339.58±273.28b
105.43±15.25a
25.43±12.31a
11.58±2.73a
Notes: NC group wasn't given any kind of medicines; AS group (one hundred twenty patients with AS) wasn't given any kind of medi-
cines before grouping. AS: ankylosing spondylitis; NC: normal control; FVC: forced vital capacity; FEV1: forced expiratory volume in 1
second; MVV: maximal voluntary ventilation; PEF: peak expiratory flow; FEF25: forced expiratory flow at 25% of forced vital capacity;
FEF50: forced expiratory flow at 50% of forced vital capacity; FEF75: forced expiratory flow at 75% of forced vital capacity; NF-κB p65: nu-
clear factor-κB p65; iNOS: inducible nitric oxide synthase; NO: nitric oxide; ROS: reactive oxygen species; RNS: reactive nitrogen spe-
cies; MDA: malondialdehyde; SOD: superoxide dismutase; CAT: catalase; TAOC: total anti-oxidative capacity; IL-1β: interleukin-1β;
TNF-α: tumor necrosis factor-α; IL-4: interleukin-4; IL-10: interleukin-10; ESR: erythrocyte sedimentation rate; Hs-CRP: high-sensitivi-
ty C-reactive protein. Compared with the NC group, aP<0.01, bP<0.05.
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it is easily affected, and pathological changes lead to
changes in pulmonary function. The results of this
study indicate that, compared with the NC group,
FEV1, MVV, PEF, FEF50, and FEF75 values in patients
with AS were significantly higher, suggesting decreased
pulmonary function.
Compared with the NC group, serum ROS, RNS, and
MDA values were significantly higher, and SOD,
CAT, and TAOC were significantly lower in patients
with AS. ROS, RNS, and MDA reflect oxidative lev-
els, while SOD, CAT, TAOC reflect anti-oxidative lev-
el.15,16 Patients with AS have increased oxidative levels
and significant decreases in anti-oxidative ability. In
this study, the results showed that patients with AS
Index
FVC (mL)
FEV1 (mL)
MVV (mL)
PEF (mL/s)
FEF25 (mL/s)
FEF50 (mL/s)
FEF75 (mL/s)
NF-κB p65 (ng/mL)
iNOS (U/mL)
NO (μmol/l)
ROS (ng/mL)
RNS (U/mL)
MDA (nmol/mL)
SOD (U/mL)
CAT (ku/l)
TAOC (U/mL)
IL-1β (pg/mL)
TNF-α (ng/L)
IL-4 (ng/L)
IL-10 (ng/L)
ESR (mm/h)
Hs-CRP (mg/L)
VAS (point)
BASDAI (point)
BASFI (point)
BAS-G (point)
XFC group
Before treatment
88.52±27.04
81.84±18.21
86.82±21.14
64.61±13.42
84.42±23.81
82.92±25.34
75.63±21.52
3.82±1.95
22.72±12.53
274.14±179.12
3.72±0.64
130.12±21.26
31.18±18.92
131.43±38.62
219.24±128.93
2.04±0.21
3.92±2.24
276.24±161.32
338.45±275.21
107.42±16.35
24.32±11.94
11.95±2.64
6.05±1.42
6.54±1.61
6.32±1.54
6.83±1.52
After treatment
89.61±26.82
105.32±17.34ab
103.16±28.23ac
88.64±18.45ac
85.53±24.25d
95.42±29.26ab
93.74±19.46ab
2.42±1.06ac
15.42±9.45ab
188.24±91.53ab
2.81±0.16ac
94.72±6.67ab
9.26±5.24ab
173.41±47.67ab
301.62±141.64ab
3.12±0.83ab
2.21±1.45ab
62.41±21.15ab
397.56±269.62ab
176.32±41.56ab
7.15±2.53ab
1.52±0.45ac
2.16±1.04ab
2.54±1.36ac
2.24±1.06ab
3.23±1.31ab
Salazopyrin group
89.91±25.64
83.02±19.41
87.73±19.32
65.47±12.63
83.26±24.91
83.63±24.61
76.82±20.37
3.72±2.14
22.91±12.24
276.42±177.91
3.92±0.54
131.72±19.54
32.41±17.64
132.82±37.24
224.61±122.82
2.14±0.12
3.84±2.36
279.34±157.36
342.64±269.93
105.93±17.62
25.82±10.25
11.44±2.98
5.96±1.45
6.42±1.84
6.24±1.53
6.94±1.52
Before treatment After treatment
91.32±23.81
98.83±18.42a
100.71±26.64a
82.45±16.32a
85.04±24.73d
90.46±28.22a
88.02±18.46a
2.63±1.32a
19.73±10.42d
217.43±102.52a
3 .02±0.44d
112.36±8.42a
14.72±8.28a
158.64±39.57a
278.53±131.73a
2.93±0.46d
2.82±1.84d
106.61±49.72a
378.65±258.91d
158.33±38.35a
9.25±3.14a
1.94±0.96a
3.14±1.26a
2.92±1.43a
3.25±1.24a
4.22±1.53a
Table 2 Comparisons of pulmonary function parameters, peripheral blood oxidative stress, and other indexes before and after
treatment in the two treatment groups (n=60, xˉ ±s)
Notes: XFC group was given standard treatment plus XFC, 3 capsules each time, three times a day with 3 months constituting one course.
Salazopyrin group was given standard treatment plus Salazopyrin, 4 tablets each time, twice per day with 3 months constituting one
course. FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; MVV: maximal voluntary ventilation; PEF: peak expirato-
ry flow; FEF25: forced expiratory flow at 25% of forced vital capacity; FEF50: forced expiratory flow at 50% of forced vital capacity; FEF75:
forced expiratory flow at 75% of forced vital capacity; NF-κB p65: nuclear factor-κB p65; iNOS: inducible nitric oxide synthase; NO: ni-
tric oxide; ROS: reactive oxygen species; RNS: reactive nitrogen species; MDA: malondialdehyde; SOD: Superoxide dismutase; CAT: cata-
lase; TAOC: total anti-oxidative capacity; IL-1β: interleukin-1β; TNF-α: tumor necrosis factor-α; IL-4: interleukin-4; IL-10: interleu-
kin-10; ESR: erythrocyte sedimentation rate; Hs-CRP: high-sensitivity C-reactive protein; VAS: visual analog scales; BASDAI: bath anky-
losing spondylitis disease active index; BASFI: bath ankylosing spondylitis functional index; BAS-G: bath ankylosing spondylitis global in-
dex; XFC: Xinfeng capsules. Compared with pre-treatment in the same group, aP<0.01, cP<0.05; compared with after treatment in the Sal-
azopyrin group, bP<0.01, cP<0.05.
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have significantly higher expression levels of peripheral
blood NF-κB p65, iNOS, and NO compared with the
NC group. Further, FEV1, MVV, PEF, FEF25, FEF50,
and FEF75 were negatively correlated with NF-κB p65,
iNOS, and NO, indicating that in AS patients with de-
creased pulmonary functions, there is activation of the
NF-κB-iNOS-NO signaling pathway. Table 4 shows
that in patients AS, the expression of the NF-κB
p65-iNOS-NO signaling pathway indexes was positive-
ly correlated with oxidative indexes, inflammatory cyto-
kines, inflammatory factors, and negatively with an-
ti-oxidative indexes, and anti-inflammatory factors.
Stimulation of ROS, RNS, and other free radicals pos-
sibly induces activation of the NF-κB p65-iNOS-NO
signaling pathway and strengthens T cell activation,
leading to infiltration and aggregation of T cells and se-
cretion of inflammatory factors. These changes damage
SOD and CAT, and produce excessive MDA, which
worsens AS and decreases pulmonary function.
XFC could significantly decrease cumulative scores of
VAS, BASDAI, BASFI, and BAS-G in patients with
AS. Moreover, XFC was significantly more effective
than Salazopyrin for decreases in the levels of NF-κB
p65-iNOS-NO signaling pathway indexes, inflamma-
tory cytokines, and oxidative indexes, and in increases
in levels of anti-inflammatory cytokines and anti-oxida-
tive indexes. XFC consists of Huangqi (Radix Astragali
Mongolici), Yiyiren (Semen Coicis), Leigongteng (Radix
et Rhizoma Tripterygii) and Wugong (Scolopendra).
Clinically, XFC has better therapeutic effects on AS
than conventional drugs.17,18 Modern pharmacologic
study indicates that Huangqi (Radix Astragali Mongoli-
ci) polysaccharides can increase SOD activity, which in-
hibits damage of cartilage cells and matrixes induced
by oxygen free radicals.19 In an animal experiment,20
Yiyiren (Semen Coicis) oil was found to reduce produc-
tion of lipid peroxides possibly by strengthening the re-
moval of endogenous active oxygen free radicals. An-
other study showed that celastrol, which is found in
Leigongteng (Radix et Rhizoma Tripterygii), can reduce
Table 3 Correlativity of pulmonary function parameters to oxidative stress indexes, cytokines, inflammatory indexes, and symp-
tom and sign cumulative scores in patients with AS
Index
NF-κB p65 (ng/mL)
iNOS (U/mL)
NO (μmol/l)
ROS (ng/mL)
RNS (U/mL)
MDA (nmol/mL)
SOD (U/mL)
CAT (ku/L)
TAOC (U/mL)
IL-1β (pg/mL)
TNF-α (ng/L)
IL-4 (ng/L)
IL-10 (ng/L)
ESR (mm/h)
Hs-CRP (mg/L)
VAS (point)
BASDAI (point)
BASFI (point)
BAS-G (point)
FVC
(mL)
﹣0.254
﹣0.237
﹣0.276
﹣0.257
﹣0.231
﹣0.256
0.244
0.237
0.283
﹣0.281
﹣0.265
0.291
0.231
﹣0.279
﹣0.246
﹣0.317a
﹣0.286
﹣0.236
﹣0.283
FEV1
(mL)
﹣0.386a
﹣0.415b
﹣0.397a
﹣0.365a
﹣0.358a
﹣0.343a
﹣0.432b
﹣0.314a
﹣0.346a
﹣0.339a
﹣0.343a
﹣0.335a
﹣0.346a
﹣0.325a
﹣0.361a
﹣0.416b
﹣0.356a
﹣0.342a
﹣0.276
MVV
(mL)
﹣0.367a
-0.371a
-0.393a
﹣0.341a
﹣0.299
﹣0.335a
0.385a
0.297
0.348a
﹣0.352a
﹣0.316a
0.339a
0.357a
﹣0.324a
﹣0.283
﹣0.357a
﹣0.372a
﹣0.281
﹣0.265
PEF
(mL/s)
﹣0.348a
﹣0.369a
﹣0.375a
﹣0.319a
﹣0.263
﹣0.306
0.349a
0.316a
0.265
﹣0.305a
﹣0.237
0.348a
0.263
﹣0.271
﹣0.274
﹣0.371a
﹣0.346a
﹣0.297
﹣0.244
FEF25
(mL/s)
﹣0.276
﹣0.243
﹣0.274
﹣0.203
﹣0.193
﹣0.206
0.288
0.257
0.261
﹣0.278
﹣0.242
0.276
0.257
﹣0.183
﹣0.263
﹣0.325a
﹣0.291
﹣0.289
﹣0.178
FEF50
(mL/s)
﹣0.389a
﹣0.392a
﹣0.385a
﹣0.351a
﹣0.315a
﹣0.352a
0.335a
0.318a
0.349a
﹣0.361a
﹣0.334a
0.318a
0.285
﹣0.216
﹣0.258
﹣0.352a
﹣0.376a
﹣0.382a
﹣0.192
FEF75
(mL/s)
﹣0.362a
﹣0.358a
﹣0.347a
﹣0.361a
﹣0.348a
﹣0.291
0.339a
0.293
0.254
﹣0.274
﹣0.258
0.285
0.241
﹣0.259
﹣0.171
﹣0.376a
﹣0.381a
﹣0.397a
﹣0.229
Notes: AS: ankylosing spondylitis; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; MVV: maximal voluntary ven-
tilation; PEF: peak expiratory flow; FEF25: forced expiratory flow at 25% of forced vital capacity; FEF50: forced expiratory flow at 50% of
forced vital capacity; FEF75: forced expiratory flow at 75% of forced vital capacity; NF-κB p65: Nuclear Factor-κB p65; iNOS: inducible
nitric oxide synthase; NO: nitric oxide; ROS: reactive oxygen species; RNS: reactive nitrogen species; MDA: malondialdehyde; SOD: su-
peroxide dismutase; CAT: catalase; TAOC: total anti-oxidative capacity; IL-1β: interleukin-1β; TNF-α: tumor necrosis factor-α; IL-4: in-
terleukin-4; IL-10: interleukin-10; ESR: erythrocyte sedimentation rate; Hs-CRP: high-sensitivity C-reactive protein. VAS: visual analog
scales; BASDAI: bath ankylosing spondylitis disease active index; BASFI: bath ankylosing spondylitis functional index; BAS-G: bath anky-
losing spondylitis global index. aP<0.05; bP<0.01.
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active oxygen free radicals produced by blood vessel
smooth muscle, and secretion of inflammation-promot-
ing cytokine TNF-α.21 Further study indicated that
acidic proteins contained in Wugong (Scolopendra) can
significantly increase the anti-oxidative index SOD, de-
crease expressions of oxidative indexes MDA, NOS,
and NO, and alleviate tissue injury induced by lipid
peroxidation.22 XFC can therefore decrease the expres-
sion of the NF-κB p65-iNOS-NO signaling pathway
in the peripheral blood of AS patients, and correct im-
balances in T cell subgroups secreting cytokines and ox-
idative stress.
Patients with AS have local lesions in the signal cord
and other joints, with decreases in pulmonary func-
tions, which are negatively correlated with the
NF-κB-iNOS-NO signaling pathway, oxidative index-
es, and inflammatory cytokines. Compared with Sala-
zopyrin, XFC can more effectively improve pulmonary
functions while improving pain in spinal cord joints
and other symptoms and laboratory indexes in patients
with AS. The mechanism is possibly via inhibition of
the NF-κB-iNOS-NO signaling pathway; down-regu-
lation of the levels of oxidative indexes, inflammatory
cytokines, and inflammatory indexes; up-regulation of
the levels of anti-oxidative indexes and anti-inflamma-
tory cytokines; strengthening anti-oxidative ability; cor-
recting imbalances in cytokine levels; decreasing in-
flammatory indexes and abnormal sedimentation of im-
mune compounds; and reducing injured pulmonary tis-
sues.
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